Clinically, this suggests that treatment with anti-PD-1 immunotherapy could be greatly enhanced by combining anti-PD-1 with T cell trafficking agents to promote greater T cell infiltration into the tumor microenvironment to aid tumor resident PD-1—and PD-1intermediate CD4 effectors perform supportive functions. Here, CD4 is linked to neoplasm.